Market Intelligence, Clinical Progress, and High-Purity Reagents for Adhesion GPCR & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADGRB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADGRB1 ECD-Fc Fusion Protein (full-length & fragments). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Contains TSP1 repeats for PS binding. HEK293 expressed. | View ADGRB1 Products |
| Gene Delivery | ADGRB1 Promise-ORF Lentivirus. Full-length ORF with 7TM domains for stable cell lines. Retains native conformation and post-translational modification. | View ADGRB1 Products |
| Benchmark Ab | Anti-ADGRB1 Recombinant Antibody. Recombinant positive control for flow cytometry and binding assay development. | View ADGRB1 Products |
| Validator | ADGRB1 siRNA Set. For knockdown verification in phagocytosis and signaling assays. | View ADGRB1 Products |
| Subfamily Control 1 | ADGRB2 (BAI2) ECD-Fc Protein. For selectivity screening vs. related adhesion GPCRs. | View ADGRB2 Products |
| Subfamily Control 2 | ADGRB3 (BAI3) ECD-Fc Protein. Critical for BAI subfamily counter-screening. | View ADGRB3 Products |
| Pathway Partner | MERTK (c-Mer). TAM receptor tyrosine kinase; synergistic phagocytosis pathway. | View MERTK Products |
| Pathway Partner | CD47. Synergistic macrophage checkpoint (efferocytosis). | View CD47 Products |
| Competing Receptor | TIMD4 (TIM-4). Alternative phosphatidylserine receptor; functional comparison studies. | View TIMD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Complex GPCR | Lentivirus stable cell lines preserve multi-pass membrane topology and GPS autoproteolysis. |
| Extracellular Domain (TSP1) Mapping | HEK293 Expressed (Native Glycosylation), sequence-verified truncated ECD panels. |
| Subfamily Selectivity (BAI1 vs BAI2/3) | Strictly sequence-verified human ADGRB1/2/3 ortholog panel. High purity (>95%). |
| Cross-species CNS Translation (Human/Mouse/Cyno) | Ortholog proteins available with >95% purity; Sequence conservation verified. |
| Functional Phagocytosis Validation | Lentivirus for stable ADGRB1-expressing cell lines; Endotoxin controlled <1EU/ul. |
| Lack of Controls / Assay Drift | Clinical Benchmark Antibodies (Biosimilars) included; Validated siRNA for specificity. |
| Lipid Vesicle Binding Artifacts | High-purity ECD-Fc with low aggregate content (<5%); Suitable for SPR/BLI. |
Live ADGRB1/BAI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADGRB1 (BAI1) therapeutics is intensifying, with major players shifting focus from traditional anti-angiogenic mAbs to novel modalities targeting the tumor microenvironment (TME) and microglial phagocytosis. As an Adhesion GPCR that regulates efferocytosis (the clearance of apoptotic cells) and suppresses angiogenesis, ADGRB1 is emerging as a critical innate immune checkpoint. The next wave of R&D is targeting macrophage repolarization in solid tumors (e.g., glioblastoma multiforme) and microglial modulation in neurodegeneration (e.g., Alzheimer's disease). Understanding of "eat-me" signal recognition expands beyond oncology, opening opportunities for brain-penetrant biologics and allosteric modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Agonistic) | Early-stage Biotechs, Academic Labs | Glioblastoma, Alzheimer's Disease | Macrophage/Microglial Activation Assay (Need GPCR lentivirus for reporter cells) |
| ECD Decoy / Trap | Preclinical Programs | Angiogenesis inhibition | PS Binding Affinity (Need properly folded TSP1 domain proteins) |
| CAR-T / Cell Therapy | Cell Therapy Innovators | Refractory Solid Tumors | Target Recognition Assay (Need native conformation via stable cells) |
| Small Molecules | Academic-Industry Spin-offs | Neuroinflammation | Selectivity Assay (Need Sequence-Verified homologous proteins) |
| Gene Therapy | Neuro-focused Gene Therapy Firms | Microglial Activation Disorders | Cell Line Construction (Need high-titer ADGRB1 Lentivirus) |